| Name | Title | Contact Details |
|---|
Anuncia Medical, Inc., an emerging leader in Cerebrospinal Fluid (CSF) management
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
Sunrise Medical designs and manufactures mobility products including lightweight wheelchairs, power wheelchairs, pediatric wheelchairs, wheelchair cushions and positioning supports.
Avante is a single source provider of surgical, diagnostic imaging and radiation oncology equipment. Sales, service, repair, parts, installation.
Specializing in Respiratory, Patient Monitoring, Diagnostic, Anesthesia, Ventilation Biomedical and Plastic Surgery Products.